uploads/2018/09/Intellia.png

A Financial Overview of Intellia Therapeutics in September

By

Updated

Revenue trends

In the second quarter, Intellia Therapeutics (NTLA) reported collaboration revenue of $7.7 million compared to $5.9 million in the second quarter of 2017. Intellia Therapeutics’ collaboration agreement with Regeneron Pharmaceuticals (REGN) primarily contributed to the increase in its collaboration revenue in the second quarter.

In the first half of 2018, Intellia Therapeutics reported net collaboration revenue of $15.1 million compared to $12.1 million in the first half of 2017.

Article continues below advertisement

Expense trends

In the second quarter, Intellia Therapeutics reported R&D (research and development) and G&A (general and administrative) expenses of $23.5 million and $7.8 million, respectively, compared to $15.6 million and $6.4 million, respectively, in the second quarter of 2017.

In the first half of 2018, Intellia Therapeutics reported R&D and G&A expenses of $45.9 million and $15.2 million, respectively, compared to $29.0 million and $12.1 million, respectively, in the same period of the previous year.

Earnings trends

In the second quarter, Intellia Therapeutics reported net income and EPS of -$22.2 million and -$0.52, respectively, compared to its net income and EPS of -$15.6 million and -$0.45, respectively, in the second quarter of 2017.

In the first half of 2018, Intellia Therapeutics reported net income and EPS of -$43.6 million and -$1.3 million, respectively, compared to -$28.2 million and -$0.81, respectively, in the same period of the previous year.

Program in the pipeline

Intellia Therapeutics recently noted progress in its primary hyperoxaluria type 1 (or PH1) program, in which the company is using a phenotypic mouse model of the disease.

Intellia Therapeutics also continued the expansion of its next-generation automated sequencing and bioinformatics platform for supporting the evaluation of highly active guides that have limited off-target deletions. Intellia Therapeutics has increased its throughput capacity for processing over 30,000 sequencing samples per week. This increased capacity will allow for the calculation of on-target and off-target genome editing.

Intellia Therapeutics’ gene-editing peers CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Sangamo Therapeutics (SGMO) reported revenues of $1.09 million, $7.37 million, and $21.42 million, respectively, in the second quarter.

Advertisement

More From Market Realist